Dyshidrosiform pemphigoid due to nivolumab therapy

Eur J Dermatol. 2021 Jun 1;31(3):411-412. doi: 10.1684/ejd.2021.4052.

Authors

Wakiko Hayashi¹, Katsuhiro Yamada¹, Kenta Kumagai², Michihiro Kono¹

Affiliations

¹ Department of Dermatology and Plastic Surgery.
² Department of Gastroenterological Surgery, Akita University Graduate School of Medicine, Akita, 010-8543, Japan.

PMID: 34309527
DOI: 10.1684/ejd.2021.4052

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
Humans
Male
Nivolumab / adverse effects*
Pemphigoid, Bullous / chemically induced*
Pemphigoid, Bullous / pathology

Substances

Antineoplastic Agents, Immunological
Nivolumab